



FEP Medical Policy Manual

FEP 2.04.59 Genetic Testing for Developmental Delay/Intellectual Disability, Autism Spectrum Disorder, and Congenital Anomalies

Effective Policy Date: January 1, 2023

Original Policy Date: December 2011

Related Policies:

- 2.04.102 - Whole Exome and Whole Genome Sequencing for Diagnosis of Genetic Disorders
- 2.04.122 - Chromosomal Microarray Testing for the Evaluation of Pregnancy Loss

Genetic Testing for Developmental Delay/Intellectual Disability, Autism Spectrum Disorder, and Congenital Anomalies

Description

Description

Chromosomal microarray (CMA) testing has been proposed for the detection of genetic imbalances in infants or children with characteristics of developmental delay/intellectual disability, autism spectrum disorder, and/or congenital anomalies. CMA testing increases the diagnostic yield over karyotyping in children with the aforementioned characteristics, and CMA testing may impact clinical management decisions. Next-generation sequencing panel testing allows for the simultaneous analysis of a large number of genes and, in patients with normal CMA testing, next-generation testing has been proposed as a way to identify single-gene causes of syndromes that have autism as a significant clinical feature.

OBJECTIVE

The objective of this evidence review is to evaluate whether chromosomal microarray testing or gene panel testing with next-generation sequencing improves the net health outcome in individuals with developmental delay/intellectual disability, autism spectrum disorder, and/or congenital anomalies not specific to a well-delineated genetic syndrome.

POLICY STATEMENT

Chromosomal microarray analysis may be considered **medically necessary** as first-line testing in the initial evaluation (see Policy Guidelines) of individuals with any of the following:

- Apparent nonsyndromic developmental delay/intellectual disability,
- Autism spectrum disorder, or
- Multiple congenital anomalies not specific to a well-delineated genetic syndrome.

Chromosomal microarray is considered **investigational** for the evaluation of all other conditions of delayed development, including, but not limited to, idiopathic growth or language delay.

Panel testing using next-generation sequencing is considered **investigational** in all cases of suspected genetic abnormality in children with developmental delay/intellectual disability, autism spectrum disorder, or congenital anomalies.

POLICY GUIDELINES

Use of chromosomal microarray (CMA) testing as outlined in this policy is not intended for use in the prenatal period.

A guideline update from the American College of Medical Genetics (Schaefer et al [2013]) stated that a stepwise (or tiered) approach to the clinical genetic diagnostic evaluation of autism spectrum disorder is recommended, with the recommendation being for first tier to include fragile X syndrome and CMA testing.

Recommendations from the American College of Medical Genetics (Manning and Hudgins [2010]) on array-based technologies and their clinical utilization for detecting chromosomal abnormalities include the following: "Appropriate follow-up is recommended in cases of chromosome imbalance identified by CMA, to include cytogenetic/FISH [fluorescent in situ hybridization] studies of the patient, parental evaluation, and clinical genetic evaluation and counseling."

In some cases of CMA analysis, the laboratory performing the test confirms all reported copy number variants with an alternative technology, such as fluorescent in situ hybridization analysis.

Genetic Counseling

Genetic counseling is primarily aimed at patients who are at risk for inherited disorders, and experts recommend formal genetic counseling in most cases when genetic testing for an inherited condition is considered. The interpretation of the results of genetic tests and the understanding of risk factors can be very difficult and complex. Therefore, genetic counseling will assist individuals in understanding the possible benefits and harms of genetic testing, including the possible impact of the information on the individual's family. Genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing. Genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

Screening (other than the preventive services listed in the brochure) is not covered. Please see Section 6 General exclusions.

Benefits are available for specialized diagnostic genetic testing when it is medically necessary to diagnose and/or manage a patient's existing medical condition. Benefits are not provided for genetic panels when some or all of the tests included in the panel are not covered, are experimental or investigational, or are not medically necessary.

FDA REGULATORY STATUS

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments. Lab tests for CMA testing and next-generation sequencing are available under the auspices of Clinical Laboratory Improvement Amendments. Laboratories that offer laboratory-developed tests must be licensed by the Clinical Laboratory Improvement Amendments for high-complexity testing. To date, the U.S. Food and Drug Administration (FDA) has chosen not to require any regulatory review of this test.

In 2010, the FDA indicated that it would require microarray manufacturers to seek clearance to sell their products for use in clinical cytogenetics.

CMA Testing

CMA testing is commercially available through many laboratories and includes targeted and whole-genome arrays, with or without SNV microarray analysis.

In January 2014, the Affymetrix CytoScan Dx Assay (Thermo Fisher Scientific) was cleared by the FDA through the de novo 510(k) process. The FDA's review of the CytoScan Dx Assay included an analytic evaluation of the test's ability to detect accurately numerous chromosomal variations of different types, sizes, and genome locations compared with several analytically validated test methods. The FDA found that the CytoScan Dx Assay could detect CNVs across the genome and adequately detect CNVs in regions of the genome associated with developmental delay/intellectual disability. Reproducibility decreased with the CNV gain or loss size, particularly when less than approximately 400 kilobases (generally recommended as the lower reporting limit). As of July 2017, Affymetrix™ contains 2.7 million markers for copy number, 750,000 SNVs, and 1.9 million non-polymorphic probes (Affymetrix was acquired by Thermo Fisher Scientific in 2016). FDA product code: PFX.

FirstStep^{Dx} PLUS (Lineagen) uses Lineagen's custom-designed microarray platform manufactured by Affymetrix. As of July 2017, this microarray consists of a 2.8 million probe microarray for the detection of CNVs associated with neurodevelopmental disorders. The array includes probes that come standard on the Affymetrix CytoScan HD microarray, with an additional 88435 custom probes designed by Lineagen.

Ambry Genetics offers multiple tests (CMA and next-generation sequencing) designed for diagnosing ASD and neurodevelopmental disorders. As of July 2017, the CMA offered by Ambry Genetics includes over 2.6 million probes for copy number and 750,000 SNV probes. The expanded next-generation sequencing panel for neurodevelopmental disorders assesses 196 genes.

LabCorp offers the Reveal SNP Microarray-Pediatric for individuals with nonsyndromic congenital anomalies, dysmorphic features, developmental delay/intellectual disability, and/or ASD. The Reveal microarray has 2695 million probes as of July 2017.

Next-Generation Sequencing

A variety of commercial and academic laboratories offer next-generation sequencing panels designed for the evaluation of ASD, developmental delay/intellectual disability, and congenital anomalies, which vary in terms of the numbers of and specific genes tested.

Emory Genetics Laboratory offers a next-generation sequencing ASD panel of genes targeting genetic syndromes that include autism or autistic features. Greenwood Genetics Center offers a next-generation sequencing panel for syndromic autism that includes 83 genes. Fulgent Genetics offers a next-generation sequencing ASD panel that includes 121 genes.

RATIONALE

Summary of Evidence

For individuals who have developmental delay/intellectual disability, autism spectrum disorder (ASD), or multiple congenital anomalies not specific to a well-delineated genetic syndrome who receive chromosomal microarray (CMA) testing, the evidence includes primarily case series. Relevant outcomes are test validity, changes in reproductive decision making, morbid events, and resource utilization. The available evidence supports test validity. Although systematic studies of the impact of CMA on patient outcomes are lacking, the improvement in diagnostic yield over karyotyping has been well-demonstrated. Direct evidence of improved outcomes with CMA compared with karyotyping is also lacking. However, for at least a subset of the disorders potentially diagnosed with CMA testing in this patient population, there are well-defined and accepted management steps associated with positive test results. Further, there is evidence of changes in reproductive decision-making as a result of positive test results. The information derived from CMA testing can accomplish the following: it could end a long diagnostic odyssey, reduce morbidity for certain conditions by initiating surveillance/management of associated comorbidities, or it could impact future reproductive decision making for parents. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have developmental delay/intellectual disability, autism spectrum disorder, or multiple congenital anomalies not specific to a well-delineated genetic syndrome who receive next-generation sequencing panel testing, the evidence includes primarily case series. Relevant outcomes are test validity, changes in reproductive decision-making, morbid events, and resource utilization. The diagnostic yield associated with next-generation sequencing panel testing in this patient population is not well-characterized. The testing yield and likelihood of an uncertain result are variable, based on the gene panel, gene tested, and patient population; additionally, there are risks of uninterpretable and incidental results. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

SUPPLEMENTAL INFORMATION

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American Academy of Pediatrics

In 2014, the American Academy of Pediatrics (AAP) issued a clinical report on the optimal medical genetics evaluation of a child with developmental delays or intellectual disability.¹⁵ Regarding chromosomal microarray (CMA) testing, this report stated

"CMA now should be considered a first-tier diagnostic test in all children with [global developmental delay/intellectual disability] GDD/ID for whom the causal diagnosis is not known.... CMA is now the standard for diagnosis of patients with GDD/ID, as well as other conditions, such as autism spectrum disorders or multiple congenital anomalies."

In 2020, the AAP issued a clinical report on identifying infants and young children with developmental disorders through surveillance and screening.¹⁰⁹ The report proposed a screening model that included performing a complete medical evaluation and stated that a

"child with suspected global developmental delay or intellectual disability should have laboratory testing done, including chromosomal microarray and fragile X testing [...] Further testing may be indicated when a diagnosis is not established with initial laboratory evaluation including whole exome sequencing and gene panels."

American Academy of Child and Adolescent Psychiatry

In 2014, the American Academy of Child and Adolescent Psychiatry updated its guidelines on the assessment and treatment of children and adolescents with autism spectrum disorder (ASD).¹¹⁰ The Academy recommended that "all children with ASD should have a medical assessment, which typically includes physical examination, a hearing screen, a Wood's lamp examination for signs of tuberous sclerosis, and genetic testing, which may include G-banded karyotype, fragile X testing, or chromosomal microarray."

American Academy of Neurology and Child Neurology Society

In 2011, the American Academy of Neurology and the Child Neurology Society updated their guidelines on the evaluation of unexplained developmental delay and intellectual disability with information on genetic and metabolic (biochemical) testing to accommodate advances in the field.¹¹¹ The guidelines concluded that CMA testing has the highest diagnostic yield in children with developmental delay/intellectual disability, that the "often complex results require confirmation and careful interpretation, often with the assistance of a medical geneticist," and that CMA should be considered the "first-line" test. The guidelines acknowledged that "Research is sorely lacking on the medical, social, and financial benefits of having an accurate etiologic diagnosis."

American College of Medical Genetics

The American College of Medical Genetics (ACMG) (2010; reaffirmed 2020) published a clinical practice resource on array-based technologies and their clinical utilization for detecting chromosomal abnormalities.^{112,113} CMA testing for copy number variants was recommended as a first-line test in the initial postnatal evaluation of individuals with the following:

- Multiple anomalies not specific to a well-delineated genetic syndrome
- Apparently nonsyndromic developmental delay/intellectual disability
- Autism spectrum disorder (ASD)

Other ACMG guidelines have addressed the design and performance expectations for clinical microarrays and associated software^{8,114}, and for the interpretation and reporting of copy number variants,¹¹ both intended for the postnatal setting.

A 2013 update included recommendations on the validation of microarray methodologies for both prenatal and postnatal specimens.¹¹⁵ The guideline revisions from ACMG (2013) stated that a stepwise or tiered approach to the clinical genetic diagnostic evaluation of ASD is recommended, with the first tier including fragile X syndrome and CMA, and the second tier *MECP2* and *PTEN* testing.¹¹⁶ The guidelines stated that:

"this approach will evolve with continued advancements in diagnostic testing and improved understanding of the ASD phenotype. Multiple additional conditions have been reported in association with an ASD phenotype, but none of these has been evaluated in a large prospective cohort. Therefore, a future third tier of evaluation is a distinct possibility. Further studies would be needed to elevate the evidence to the point of recommended testing. Alternatively, advances in technology may permit bundling of individual tests into an extended, more readily accessible, and less expensive platform. The accumulating evidence using next-generation sequencing (third-tier testing) will increase the diagnostic yield even more over the next few years."

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

REFERENCES

1. Mikhail FM, Lose EJ, Robin NH, et al. Clinically relevant single gene or intragenic deletions encompassing critical neurodevelopmental genes in patients with developmental delay, mental retardation, and/or autism spectrum disorders. *Am J Med Genet A*. Oct 2011; 155A(10): 2386-96. PMID 22031302
2. Brandler WM, Sebat J. From de novo mutations to personalized therapeutic interventions in autism. *Annu Rev Med*. 2015; 66: 487-507. PMID 25587659
3. Stankiewicz P, Beaudet AL. Use of array CGH in the evaluation of dysmorphism, malformations, developmental delay, and idiopathic mental retardation. *Curr Opin Genet Dev*. Jun 2007; 17(3): 182-92. PMID 17467974
4. Stuart SW, King CH, Pai GS. Autism spectrum disorder, Klinefelter syndrome, and chromosome 3p21.31 duplication: a case report. *MedGenMed*. Dec 18 2007; 9(4): 60. PMID 18311409
5. Moeschler JB. Medical genetics diagnostic evaluation of the child with global developmental delay or intellectual disability. *Curr Opin Neurol*. Apr 2008; 21(2): 117-22. PMID 18317267
6. Schaefer GB, Mendelsohn NJ. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders. *Genet Med*. Apr 2008; 10(4): 301-5. PMID 18414214
7. Korf BR, Rehm HL. New approaches to molecular diagnosis. *JAMA*. Apr 10 2013; 309(14): 1511-21. PMID 23571590
8. Kearney HM, South ST, Wolff DJ, et al. American College of Medical Genetics recommendations for the design and performance expectations for clinical genomic copy number microarrays intended for use in the postnatal setting for detection of constitutional abnormalities. *Genet Med*. Jul 2011; 13(7): 676-9. PMID 21681105
9. Rodriguez-Revena L, Vallespin E, Madrigal I, et al. A parallel study of different array-CGH platforms in a set of Spanish patients with developmental delay and intellectual disability. *Gene*. May 25 2013; 521(1): 82-6. PMID 23524024
10. Kloosterman WP, Hochstenbach R. Deciphering the pathogenic consequences of chromosomal aberrations in human genetic disease. *Mol Cytogenet*. 2014; 7(1): 100. PMID 25606056
11. Kearney HM, Thorland EC, Brown KK, et al. American College of Medical Genetics standards and guidelines for interpretation and reporting of postnatal constitutional copy number variants. *Genet Med*. Jul 2011; 13(7): 680-5. PMID 21681106
12. Riggs ER, Church DM, Hanson K, et al. Towards an evidence-based process for the clinical interpretation of copy number variation. *Clin Genet*. May 2012; 81(5): 403-12. PMID 22097934
13. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). TEC Special Report: Array Comparative Genomic Hybridization (aCGH) for the Genetic Evaluation of Patients with Developmental Delay/Mental Retardation and Autism Spectrum Disorder. TEC Assessments. 2009;Volume 24;Tab 10.
14. Blue Cross and Blue Shield Association. Special Report: Chromosomal Microarray for the Genetic Evaluation of Patients With Global Developmental Delay, Intellectual Disability, and Autism Spectrum Disorder. TEC Assessments. 2015;Volume 30;Tab 2.
15. Moeschler JB, Shevell M, Moeschler JB, et al. Comprehensive evaluation of the child with intellectual disability or global developmental delays. *Pediatrics*. Sep 2014; 134(3): e903-18. PMID 25157020
16. Shevell M, Ashwal S, Donley D, et al. Practice parameter: evaluation of the child with global developmental delay: report of the Quality Standards Subcommittee of the American Academy of Neurology and The Practice Committee of the Child Neurology Society. *Neurology*. Feb 11 2003; 60(3): 367-80. PMID 12578916
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition: DSM-5. Washington (DC): American Psychiatric Association; 2013.
18. Zablotsky B, Black LI, Maenner MJ, et al. Prevalence and Trends of Developmental Disabilities among Children in the United States: 2009-2017. *Pediatrics*. Oct 2019; 144(4). PMID 31558576
19. Srour M, Shevell M. Genetics and the investigation of developmental delay/intellectual disability. *Arch Dis Child*. Apr 2014; 99(4): 386-9. PMID 24344174
20. Willemsen MH, Kleefstra T. Making headway with genetic diagnostics of intellectual disabilities. *Clin Genet*. Feb 2014; 85(2): 101-10. PMID 23895455
21. Moeschler JB. Genetic evaluation of intellectual disabilities. *Semin Pediatr Neurol*. Mar 2008; 15(1): 2-9. PMID 18342255
22. Yuen RK, Thiruvahindrapuram B, Merico D, et al. Whole-genome sequencing of quartet families with autism spectrum disorder. *Nat Med*. Feb 2015; 21(2): 185-91. PMID 25621899
23. Gaugler T, Klei L, Sanders SJ, et al. Most genetic risk for autism resides with common variation. *Nat Genet*. Aug 2014; 46(8): 881-5. PMID 25038753
24. Schaefer GB, Mendelsohn NJ. Genetics evaluation for the etiologic diagnosis of autism spectrum disorders. *Genet Med*. Jan 2008; 10(1): 4-12. PMID 18197051
25. Butler MG, Dasouki MJ, Zhou XP, et al. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. *J Med Genet*. Apr 2005; 42(4): 318-21. PMID 15805158
26. Wright CF, Fitzgerald TW, Jones WD, et al. Genetic diagnosis of developmental disorders in the DDD study: a scalable analysis of genome-wide research data. *Lancet*. Apr 04 2015; 385(9975): 1305-14. PMID 25529582
27. Eriksson MA, Lieden A, Westerlund J, et al. Rare copy number variants are common in young children with autism spectrum disorder. *Acta Paediatr*. Jun 2015; 104(6): 610-8. PMID 25661985
28. Krepischi-Santos AC, Vianna-Morgante AM, Jehee FS, et al. Whole-genome array-CGH screening in undiagnosed syndromic patients: old syndromes revisited and new alterations. *Cytogenet Genome Res*. 2006; 115(3-4): 254-61. PMID 17124408

29. Bartnik M, Nowakowska B, Derwinska K, et al. Application of array comparative genomic hybridization in 256 patients with developmental delay or intellectual disability. *J Appl Genet.* Feb 2014; 55(1): 125-44. PMID 24297458
30. Bartnik M, Wisniewiecka-Kowalnik B, Nowakowska B, et al. The usefulness of array comparative genomic hybridization in clinical diagnostics of intellectual disability in children. *Dev Period Med.* Jul-Sep 2014; 18(3): 307-17. PMID 25182394
31. Chong WW, Lo IF, Lam ST, et al. Performance of chromosomal microarray for patients with intellectual disabilities/developmental delay, autism, and multiple congenital anomalies in a Chinese cohort. *Mol Cytogenet.* 2014; 7: 34. PMID 24926319
32. D'Amours G, Langlois M, Mathonnet G, et al. SNP arrays: comparing diagnostic yields for four platforms in children with developmental delay. *BMC Med Genomics.* Dec 24 2014; 7: 70. PMID 25539807
33. Henderson LB, Applegate CD, Wohler E, et al. The impact of chromosomal microarray on clinical management: a retrospective analysis. *Genet Med.* Sep 2014; 16(9): 657-64. PMID 24625444
34. Nava C, Keren B, Mignot C, et al. Prospective diagnostic analysis of copy number variants using SNP microarrays in individuals with autism spectrum disorders. *Eur J Hum Genet.* Jan 2014; 22(1): 71-8. PMID 23632794
35. Nicholl J, Waters W, Mulley JC, et al. Cognitive deficit and autism spectrum disorders: prospective diagnosis by array CGH. *Pathology.* Jan 2014; 46(1): 41-5. PMID 24300712
36. Palmer E, Speirs H, Taylor PJ, et al. Changing interpretation of chromosomal microarray over time in a community cohort with intellectual disability. *Am J Med Genet A.* Feb 2014; 164A(2): 377-85. PMID 24311194
37. Preiksaitiene E, Molyte A, Kasnauskiene J, et al. Considering specific clinical features as evidence of pathogenic copy number variants. *J Appl Genet.* May 2014; 55(2): 189-96. PMID 24535828
38. Redin C, Gerard B, Lauer J, et al. Efficient strategy for the molecular diagnosis of intellectual disability using targeted high-throughput sequencing. *J Med Genet.* Nov 2014; 51(11): 724-36. PMID 25167861
39. Roberts JL, Hovanes K, Dasouki M, et al. Chromosomal microarray analysis of consecutive individuals with autism spectrum disorders or learning disability presenting for genetic services. *Gene.* Feb 01 2014; 535(1): 70-8. PMID 24188901
40. Stobbe G, Liu Y, Wu R, et al. Diagnostic yield of array comparative genomic hybridization in adults with autism spectrum disorders. *Genet Med.* Jan 2014; 16(1): 70-7. PMID 23765050
41. Tao VQ, Chan KY, Chu YW, et al. The clinical impact of chromosomal microarray on paediatric care in Hong Kong. *PLoS One.* 2014; 9(10): e109629. PMID 25333781
42. Utine GE, Haliloglu G, Volkan-Salanci B, et al. Etiological yield of SNP microarrays in idiopathic intellectual disability. *Eur J Paediatr Neurol.* May 2014; 18(3): 327-37. PMID 24508361
43. Uwizeza A, Caberg JH, Hitayezu J, et al. Array-CGH analysis in Rwandan patients presenting development delay/intellectual disability with multiple congenital anomalies. *BMC Med Genet.* Jul 12 2014; 15: 79. PMID 25016475
44. Battaglia A, Doccini V, Bernardini L, et al. Confirmation of chromosomal microarray as a first-tier clinical diagnostic test for individuals with developmental delay, intellectual disability, autism spectrum disorders and dysmorphic features. *Eur J Paediatr Neurol.* Nov 2013; 17(6): 589-99. PMID 23711909
45. Lee CG, Park SJ, Yun JN, et al. Array-based comparative genomic hybridization in 190 Korean patients with developmental delay and/or intellectual disability: a single tertiary care university center study. *Yonsei Med J.* Nov 2013; 54(6): 1463-70. PMID 24142652
46. Shoukier M, Klein N, Auber B, et al. Array CGH in patients with developmental delay or intellectual disability: are there phenotypic clues to pathogenic copy number variants?. *Clin Genet.* Jan 2013; 83(1): 53-65. PMID 22283495
47. Sorte HS, Gjevik E, Sponheim E, et al. Copy number variation findings among 50 children and adolescents with autism spectrum disorder. *Psychiatr Genet.* Apr 2013; 23(2): 61-9. PMID 23277134
48. Filges I, Suda L, Weber P, et al. High resolution array in the clinical approach to chromosomal phenotypes. *Gene.* Mar 10 2012; 495(2): 163-9. PMID 22240311
49. Iourov IY, Vorsanova SG, Kurinnaia OS, et al. Molecular karyotyping by array CGH in a Russian cohort of children with intellectual disability, autism, epilepsy and congenital anomalies. *Mol Cytogenet.* Dec 31 2012; 5(1): 46. PMID 23272938
50. McGrew SG, Peters BR, Crittendon JA, et al. Diagnostic yield of chromosomal microarray analysis in an autism primary care practice: which guidelines to implement?. *J Autism Dev Disord.* Aug 2012; 42(8): 1582-91. PMID 22089167
51. Tzetis M, Kitsiou-Tzeli S, Frysira H, et al. The clinical utility of molecular karyotyping using high-resolution array-comparative genomic hybridization. *Expert Rev Mol Diagn.* Jun 2012; 12(5): 449-57. PMID 22702362
52. Bremer A, Giacobini M, Eriksson M, et al. Copy number variation characteristics in subpopulations of patients with autism spectrum disorders. *Am J Med Genet B Neuropsychiatr Genet.* Mar 2011; 156(2): 115-24. PMID 21302340
53. Coulter ME, Miller DT, Harris DJ, et al. Chromosomal microarray testing influences medical management. *Genet Med.* Sep 2011; 13(9): 770-6. PMID 21716121
54. Wincent J, Anderlid BM, Lagerberg M, et al. High-resolution molecular karyotyping in patients with developmental delay and/or multiple congenital anomalies in a clinical setting. *Clin Genet.* Feb 2011; 79(2): 147-57. PMID 20486943
55. Manolakos E, Vetro A, Kefalas K, et al. The use of array-CGH in a cohort of Greek children with developmental delay. *Mol Cytogenet.* Nov 09 2010; 3: 22. PMID 21062444
56. Rosenfeld JA, Ballif BC, Torchia BS, et al. Copy number variations associated with autism spectrum disorders contribute to a spectrum of neurodevelopmental disorders. *Genet Med.* Nov 2010; 12(11): 694-702. PMID 20808228
57. Schaefer GB, Starr L, Pickering D, et al. Array comparative genomic hybridization findings in a cohort referred for an autism evaluation. *J Child Neurol.* Dec 2010; 25(12): 1498-503. PMID 20729506
58. Shen Y, Dies KA, Holm IA, et al. Clinical genetic testing for patients with autism spectrum disorders. *Pediatrics.* Apr 2010; 125(4): e727-35. PMID 20231187

59. Bruno DL, Ganesamoorthy D, Schoumans J, et al. Detection of cryptic pathogenic copy number variations and constitutional loss of heterozygosity using high resolution SNP microarray analysis in 117 patients referred for cytogenetic analysis and impact on clinical practice. *J Med Genet.* Feb 2009; 46(2): 123-31. PMID 19015223
60. Friedman J, Adam S, Arbour L, et al. Detection of pathogenic copy number variants in children with idiopathic intellectual disability using 500 K SNP array genomic hybridization. *BMC Genomics.* Nov 16 2009; 10: 526. PMID 19917086
61. Baldwin EL, Lee JY, Blake DM, et al. Enhanced detection of clinically relevant genomic imbalances using a targeted plus whole genome oligonucleotide microarray. *Genet Med.* Jun 2008; 10(6): 415-29. PMID 18496225
62. Christian SL, Brune CW, Sudi J, et al. Novel submicroscopic chromosomal abnormalities detected in autism spectrum disorder. *Biol Psychiatry.* Jun 15 2008; 63(12): 1111-7. PMID 18374305
63. Marshall CR, Noor A, Vincent JB, et al. Structural variation of chromosomes in autism spectrum disorder. *Am J Hum Genet.* Feb 2008; 82(2): 477-88. PMID 18252227
64. Pickering DL, Eudy JD, Olney AH, et al. Array-based comparative genomic hybridization analysis of 1176 consecutive clinical genetics investigations. *Genet Med.* Apr 2008; 10(4): 262-6. PMID 18414209
65. Saam J, Gudgeon J, Aston E, et al. How physicians use array comparative genomic hybridization results to guide patient management in children with developmental delay. *Genet Med.* Mar 2008; 10(3): 181-6. PMID 18344707
66. Shevell MI, Bejjani BA, Srour M, et al. Array comparative genomic hybridization in global developmental delay. *Am J Med Genet B Neuropsychiatr Genet.* Oct 05 2008; 147B(7): 1101-8. PMID 18361433
67. Aradhya S, Manning MA, Splendore A, et al. Whole-genome array-CGH identifies novel contiguous gene deletions and duplications associated with developmental delay, mental retardation, and dysmorphic features. *Am J Med Genet A.* Jul 01 2007; 143A(13): 1431-41. PMID 17568414
68. Ballif BC, Sulpizio SG, Lloyd RM, et al. The clinical utility of enhanced subtelomeric coverage in array CGH. *Am J Med Genet A.* Aug 15 2007; 143A(16): 1850-7. PMID 17632771
69. Froyen G, Van Esch H, Bauters M, et al. Detection of genomic copy number changes in patients with idiopathic mental retardation by high-resolution X-array-CGH: important role for increased gene dosage of XLMR genes. *Hum Mutat.* Oct 2007; 28(10): 1034-42. PMID 17546640
70. Hoyer J, Dreweke A, Becker C, et al. Molecular karyotyping in patients with mental retardation using 100K single-nucleotide polymorphism arrays. *J Med Genet.* Oct 2007; 44(10): 629-36. PMID 17601928
71. Lu X, Shaw CA, Patel A, et al. Clinical implementation of chromosomal microarray analysis: summary of 2513 postnatal cases. *PLoS One.* Mar 28 2007; 2(3): e327. PMID 17389918
72. Madrigal I, Rodriguez-Revena L, Armengol L, et al. X-chromosome tiling path array detection of copy number variants in patients with chromosome X-linked mental retardation. *BMC Genomics.* Nov 29 2007; 8: 443. PMID 18047645
73. Sebat J, Lakshmi B, Malhotra D, et al. Strong association of de novo copy number mutations with autism. *Science.* Apr 20 2007; 316(5823): 445-9. PMID 17363630
74. Shen Y, Irons M, Miller DT, et al. Development of a focused oligonucleotide-array comparative genomic hybridization chip for clinical diagnosis of genomic imbalance. *Clin Chem.* Dec 2007; 53(12): 2051-9. PMID 17901113
75. Thuresson AC, Bondeson ML, Edeby C, et al. Whole-genome array-CGH for detection of submicroscopic chromosomal imbalances in children with mental retardation. *Cytogenet Genome Res.* 2007; 118(1): 1-7. PMID 17901693
76. Wagenstaller J, Spranger S, Lorenz-Depiereux B, et al. Copy-number variations measured by single-nucleotide-polymorphism oligonucleotide arrays in patients with mental retardation. *Am J Hum Genet.* Oct 2007; 81(4): 768-79. PMID 17847001
77. Ballif BC, Rorem EA, Sundin K, et al. Detection of low-level mosaicism by array CGH in routine diagnostic specimens. *Am J Med Genet A.* Dec 15 2006; 140(24): 2757-67. PMID 17103431
78. Friedman JM, Baross A, Delaney AD, et al. Oligonucleotide microarray analysis of genomic imbalance in children with mental retardation. *Am J Hum Genet.* Sep 2006; 79(3): 500-13. PMID 16909388
79. Jacquemont ML, Sanlaville D, Redon R, et al. Array-based comparative genomic hybridisation identifies high frequency of cryptic chromosomal rearrangements in patients with syndromic autism spectrum disorders. *J Med Genet.* Nov 2006; 43(11): 843-9. PMID 16840569
80. Lugtenberg D, de Brouwer AP, Kleefstra T, et al. Chromosomal copy number changes in patients with non-syndromic X linked mental retardation detected by array CGH. *J Med Genet.* Apr 2006; 43(4): 362-70. PMID 16169931
81. Menten B, Maas N, Thienpont B, et al. Emerging patterns of cryptic chromosomal imbalance in patients with idiopathic mental retardation and multiple congenital anomalies: a new series of 140 patients and review of published reports. *J Med Genet.* Aug 2006; 43(8): 625-33. PMID 16490798
82. Miyake N, Shimokawa O, Harada N, et al. BAC array CGH reveals genomic aberrations in idiopathic mental retardation. *Am J Med Genet A.* Feb 01 2006; 140(3): 205-11. PMID 16419101
83. Rosenberg C, Knijnenburg J, Bakker E, et al. Array-CGH detection of micro rearrangements in mentally retarded individuals: clinical significance of imbalances present both in affected children and normal parents. *J Med Genet.* Feb 2006; 43(2): 180-6. PMID 15980116
84. Shaffer LG, Kashork CD, Saleki R, et al. Targeted genomic microarray analysis for identification of chromosome abnormalities in 1500 consecutive clinical cases. *J Pediatr.* Jul 2006; 149(1): 98-102. PMID 16860135
85. Sharp AJ, Hansen S, Selzer RR, et al. Discovery of previously unidentified genomic disorders from the duplication architecture of the human genome. *Nat Genet.* Sep 2006; 38(9): 1038-42. PMID 16906162
86. de Vries BB, Pfundt R, Leisink M, et al. Diagnostic genome profiling in mental retardation. *Am J Hum Genet.* Oct 2005; 77(4): 606-16. PMID 16175506
87. Schoumans J, Ruivenkamp C, Holmberg E, et al. Detection of chromosomal imbalances in children with idiopathic mental retardation by array based comparative genomic hybridisation (array-CGH). *J Med Genet.* Sep 2005; 42(9): 699-705. PMID 16141005
88. Tyson C, Harvard C, Locker R, et al. Submicroscopic deletions and duplications in individuals with intellectual disability detected by array-CGH. *Am J Med Genet A.* Dec 15 2005; 139(3): 173-85. PMID 16283669

89. Harada N, Hatchwell E, Okamoto N, et al. Subtelomere specific microarray based comparative genomic hybridisation: a rapid detection system for cryptic rearrangements in idiopathic mental retardation. *J Med Genet.* Feb 2004; 41(2): 130-6. PMID 14757861
90. Shaw-Smith C, Redon R, Rickman L, et al. Microarray based comparative genomic hybridisation (array-CGH) detects submicroscopic chromosomal deletions and duplications in patients with learning disability/mental retardation and dysmorphic features. *J Med Genet.* Apr 2004; 41(4): 241-8. PMID 15060094
91. Vissers LE, de Vries BB, Osoegawa K, et al. Array-based comparative genomic hybridization for the genomewide detection of submicroscopic chromosomal abnormalities. *Am J Hum Genet.* Dec 2003; 73(6): 1261-70. PMID 14628292
92. Chaves TF, Baretto N, Oliveira LF, et al. Copy Number Variations in a Cohort of 420 Individuals with Neurodevelopmental Disorders From the South of Brazil. *Sci Rep.* Nov 28 2019; 9(1): 17776. PMID 31780800
93. Hu T, Zhang Z, Wang J, et al. Chromosomal Aberrations in Pediatric Patients with Developmental Delay/Intellectual Disability: A Single-Center Clinical Investigation. *Biomed Res Int.* 2019; 2019: 9352581. PMID 31781653
94. Xu M, Ji Y, Zhang T, et al. Clinical Application of Chromosome Microarray Analysis in Han Chinese Children with Neurodevelopmental Disorders. *Neurosci Bull.* Dec 2018; 34(6): 981-991. PMID 29948840
95. Sansovic I, Ivankov AM, Bobinec A, et al. Chromosomal microarray in clinical diagnosis: a study of 337 patients with congenital anomalies and developmental delays or intellectual disability. *Croat Med J.* Jun 14 2017; 58(3): 231-238. PMID 28613040
96. Ho KS, Twede H, Vanzo R, et al. Clinical Performance of an Ultrahigh Resolution Chromosomal Microarray Optimized for Neurodevelopmental Disorders. *Biomed Res Int.* 2016; 2016: 3284534. PMID 27975050
97. Ho KS, Wassman ER, Baxter AL, et al. Chromosomal Microarray Analysis of Consecutive Individuals with Autism Spectrum Disorders Using an Ultra-High Resolution Chromosomal Microarray Optimized for Neurodevelopmental Disorders. *Int J Mol Sci.* Dec 09 2016; 17(12). PMID 27941670
98. Hu G, Fan Y, Wang L, et al. Copy number variations in 119 Chinese children with idiopathic short stature identified by the custom genome-wide microarray. *Mol Cytogenet.* 2016; 9: 16. PMID 26884814
99. Lu XY, Phung MT, Shaw CA, et al. Genomic imbalances in neonates with birth defects: high detection rates by using chromosomal microarray analysis. *Pediatrics.* Dec 2008; 122(6): 1310-8. PMID 19047251
100. Gogarty B. Parents as partners. A report and guidelines on the investigation of children with developmental delay; by parents, for professionals Cambridge: Cambridge Genetics Knowledge Park; 2006.
101. Mroch AR, Flanagan JD, Stein QP. Solving the puzzle: case examples of array comparative genomic hybridization as a tool to end the diagnostic odyssey. *Curr Probl Pediatr Adolesc Health Care.* Mar 2012; 42(3): 74-8. PMID 22325475
102. Turner G, Boyle J, Partington MW, et al. Restoring reproductive confidence in families with X-linked mental retardation by finding the causal mutation. *Clin Genet.* Feb 2008; 73(2): 188-90. PMID 18070138
103. Lingen M, Albers L, Borchers M, et al. Obtaining a genetic diagnosis in a child with disability: impact on parental quality of life. *Clin Genet.* Feb 2016; 89(2): 258-66. PMID 26084449
104. Hayeems RZ, Hoang N, Chenier S, et al. Capturing the clinical utility of genomic testing: medical recommendations following pediatric microarray. *Eur J Hum Genet.* Sep 2015; 23(9): 1135-41. PMID 25491637
105. Ellison JW, Ravnan JB, Rosenfeld JA, et al. Clinical utility of chromosomal microarray analysis. *Pediatrics.* Nov 2012; 130(5): e1085-95. PMID 23071206
106. Hoffmann TJ, Windham GC, Anderson M, et al. Evidence of reproductive stoppage in families with autism spectrum disorder: a large, population-based cohort study. *JAMA Psychiatry.* Aug 2014; 71(8): 943-51. PMID 24942798
107. Grozeva D, Carss K, Spasic-Boskovic O, et al. Targeted Next-Generation Sequencing Analysis of 1,000 Individuals with Intellectual Disability. *Hum Mutat.* Dec 2015; 36(12): 1197-204. PMID 26350204
108. Kalsner L, Twachtman-Bassett J, Tokarski K, et al. Genetic testing including targeted gene panel in a diverse clinical population of children with autism spectrum disorder: Findings and implications. *Mol Genet Genomic Med.* Mar 2018; 6(2): 171-185. PMID 29271092
109. Lipkin PH, Macias MM, Norwood KW, et al. Promoting Optimal Development: Identifying Infants and Young Children With Developmental Disorders Through Developmental Surveillance and Screening. *Pediatrics.* Jan 2020; 145(1). PMID 31843861
110. Volkmar F, Siegel M, Woodbury-Smith M, et al. Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder. *J Am Acad Child Adolesc Psychiatry.* Feb 2014; 53(2): 237-57. PMID 24472258
111. Michelson DJ, Shevell MI, Sherr EH, et al. Evidence report: Genetic and metabolic testing on children with global developmental delay: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. *Neurology.* Oct 25 2011; 77(17): 1629-35. PMID 21956720
112. Manning M, Hudgins L. Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. *Genet Med.* Nov 2010; 12(11): 742-5. PMID 20962661
113. Manning M, Hudgins L. Addendum: Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. *Genet Med.* Dec 2020; 22(12): 2126. PMID 32514088
114. Waggoner D, Wain KE, Dubuc AM, et al. Yield of additional genetic testing after chromosomal microarray for diagnosis of neurodevelopmental disability and congenital anomalies: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). *Genet Med.* Oct 2018; 20(10): 1105-1113. PMID 29915380
115. South ST, Lee C, Lamb AN, et al. ACMG Standards and Guidelines for constitutional cytogenomic microarray analysis, including postnatal and prenatal applications: revision 2013. *Genet Med.* Nov 2013; 15(11): 901-9. PMID 24071793
116. Schaefer GB, Mendelsohn NJ. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions. *Genet Med.* May 2013; 15(5): 399-407. PMID 23519317

POLICY HISTORY - THIS POLICY WAS APPROVED BY THE FEP® PHARMACY AND MEDICAL POLICY COMMITTEE ACCORDING TO THE HISTORY BELOW:

Date	Action	Description
December 2011	New policy	
March 2013	Replace policy	Policy updated with literature search, references 11, 32, 35, 37, 38 and 40 added, No change in policy statement.
June 2014	Replace policy	Policy updated with literature review; references 36, 40, 43 and 44 added. Policy statement added that NGS panel testing is considered investigational in all cases of suspected genetic abnormality in children with developmental delay/intellectual disability or autism spectrum disorder. Title changed to include NGS.
December 2015	Replace policy	Policy updated with literature review through June 15, 2015. Policy statements changed that CMA may be considered medically necessary for apparently nonsyndromic developmental delay/intellectual disability, autism spectrum disorder, and multiple anomalies not specific to a well delineated genetic syndrome. Reference 33 was added. Policy title updated.
December 2016	Replace policy	Policy updated with literature review through July 10, 2016. References 6, 16, 21, 23-24, 33-35, and 40-42 added. Policy statements unchanged. Title changed to "Genetic Testing for Developmental Delay/Intellectual Disability, Autism Spectrum Disorder, and Congenital Anomalies".
December 2017	Replace policy	Policy updated with literature review through June 22, 2017; references 26-27 and 40 added; some references removed. Whole-exome sequencing is addressed separately in policy No. 2.04.102. The term "postnatal" removed from the policy statement. A second statement was added that chromosomal microarray is investigational for the evaluation of all other conditions of developmental delay.
December 2018	Replace policy	Policy updated with literature review through August 6, 2018; references 98-99 and 110 added. Policy statements unchanged.
December 2019	Replace policy	Policy updated with literature review through August 5, 2019; no references added. Policy statements unchanged.
December 2020	Replace policy	Policy updated with literature review through August 18, 2020; references added. Policy statements unchanged.
December 2021	Replace policy	Policy updated with literature review through August 20, 2021; no references added. Policy statements unchanged.
December 2022	Replace policy	Policy updated with literature review through August 22, 2022; references added. Policy statements unchanged.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.